<DOC>
	<DOCNO>NCT01308437</DOCNO>
	<brief_summary>This open label , randomize , parallel group comparison immunogenicity safety Wockhardt 's human insulin isophane insulin compare Novo Nordisk 's yeast base human insulin product ( market USA ) type 1 diabetic . There two phase study , follow : 1 . Phase 1 comparative phase 2 arm ( described section ) . 2 . Phase 2 follow phase applicable Wosulin Arm . The study last 54 week patient enrol Wosulin arm approximately 28 week patient enrol comparator arm . Two hundred forty two patient enrol consider estimate dropout rate 15 % sample size approximately 105 evaluable patient per arm . The total planned enrollment period study approximately 3 month ( 90 day ) .</brief_summary>
	<brief_title>Immunosafety Study Recombinant Human Insulins Type 1 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Subjects understand nature study willing provide write informed consent . 2 . Subjects prediagnosed case type1 diabetes ( fast Cpeptide &lt; 0.5 nmol/L ) insulin regimen least 12 month prior inclusion trial . 3 . Subjects stable regimen recombinant human insulin analog least 3 month prior randomization . ( A stable regimen define dose within +/ 10 % ) . 4 . Male female subject ≥ 18 &lt; 55 year age . 5 . Subjects body mass index ( BMI ) ≥18.0 &lt; 35.0 kg/m2 6 . Subjects glycosylated hemoglobin ( HbA1c ) level ≥6.5 &lt; 9.5 % 7 . Subjects cooperative , reliable , agree regular injection insulin willing comply protocol procedure . 8 . Female subject pregnant nonlactating adequate protection conception fulfil one follow criterion also eligible within ≥ 18 &lt; 55 year age limit : 1 . Women childbearing potential acceptable method birth control ( include limit barriermethod , contraceptive , intrauterine device ) 2 . Women history bilateral tubal ligation , 3 . Women undergone total hysterectomy 4 . Women two year postmenopausal 9 . Subjects able use self glucosemonitoring device self inject insulin . 1 . Female subject pregnant ( confirm positive urine serum βHCG ) currently breastfeed . 2 . Compromised hepatic renal function , show limited : i.Baseline AST ALT &gt; 3 time upper limit normal range , and/or ii.Serum Creatinine &gt; 2.0 mg/dl and/or iii.BUN &gt; 30 mg/dl Abnormal laboratory finding discuss medical monitor prior subject 's entry . 3 . Employee Investigator direct involvement trial trial direction Investigator . 4 . Those treated investigational agent device within previous 30 day , screen , plan use investigational drug device , previously randomize trial . 5 . History evidence allergy insulin preparation . 6 . History evidence severe hypoglycemia ( severe hypoglycemic episode define subject require glucose , glucagon , orange juice etc administer second person ) 7 . Requirement total daily dose insulin &gt; 1.4 units/kg 8. Who receive Wockhardt 's ( Wosulin ) Novo Nordisk 's Insulin ( Novolin® R , Novolin® N , Novolin® 70/30 , US Actrapid® Insulatard® , Mixtard® India ) previous one year . 9 . Serum AIA level &gt; 20 microU/ml . 10 . Receipt insulin animal origin last 3 year . 11 . Currently receive receive within last year immunomodulators medication , include corticosteroid would possibly modify antibody generation either enrollment course study . ( Topical/ ophthalmic/intraarticular/nasal spray corticosteroid allow ) . 12 . Hepatitis B Hepatitis C HIV positive . 13 . Oral hypoglycaemic agent within 4 week prior sign consent form . 14. Who undergo pancreatectomy pancreas/islet cell transplant . 15 . Unlikely comply study protocol e.g . unable return periodically subsequent visit . 16 . History evidence active severe proliferative retinopathy , nephropathy and/or neuropathy significant cardiovascular disease , anemia hemoglobinopathy , uncontrolled hypothyroidism uncontrolled hyperthyroidism , alcohol drug abuse medical condition opinion Investigator interfere study . 17 . Judged investigator inappropriate participate study reason mention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>